Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.

Sholter, Dalton; Wu, Jianmin; Jia, Bochao; Zhang, Hong; Griffing, Kirstin; Birt, Julie; Reis, Paulo Jorge Simoes; Liu, Huaxiang; Bingham, Clifton O

Sholter, Dalton; Wu, Jianmin; Jia, Bochao; Zhang, Hong; Griffing, Kirstin; Birt, Julie; Reis, Paulo Jorge Simoes; Liu, Huaxiang; Bingham, Clifton O.

Afiliação

Sholter D; Division of Rheumatology, Faculty of Medicine and Dentistry, University of Alberta, 10839 124 Street NW, Edmonton, AB, T5M 0H4, Canada. dsholter@ualberta.ca.
Wu J; , Edmonton, AB, T6G 2R3, Canada. dsholter@ualberta.ca.
Jia B; Eli Lilly and Company, Indianapolis, IN, USA.
Zhang H; Eli Lilly and Company, Indianapolis, IN, USA.
Griffing K; TechData Service, King of Prussia, PA, USA.
Birt J; Eli Lilly and Company, Indianapolis, IN, USA.
Reis PJS; Eli Lilly and Company, Indianapolis, IN, USA.
Liu H; Eli Lilly and Company, Indianapolis, IN, USA.
Bingham CO; Qilu Hospital of Shandong University, Jinan, China.

Rheumatol Ther ; 9(2): 541-553, 2022 Apr.

Article em En | MEDLINE | ID: mdl-34990002

Palavras-chave

Baricitinib; Janus kinase inhibitors; Minimal clinically important differences; Patient-reported outcomes; Rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article